Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Abstract
No curative treatment exists for glioblastoma, with median survival times of less than 2 years from diagnosis. As an approach to develop immune-based therapies for glioblastoma, we sought to target antigens expressed in glioma stem cells (GSCs). GSCs have multiple properties that make them significantly more representative of glioma tumors than established glioma cell lines. Epidermal growth factor receptor variant III (EGFRvIII) is the result of a novel tumor-specific gene rearrangement that produces a unique protein expressed in approximately 30% of gliomas, and is an ideal target for immunotherapy. Using PCR primers spanning the EGFRvIII-specific deletion, we found that this tumor-specific gene is expressed in three of three GCS lines. Based on the sequence information of seven EGFRvIII-specific monoclonal antibodies (mAbs), we assembled chimeric antigen receptors (CARs) and evaluated the ability of CAR-engineered T cells to recognize EGFRvIII. Three of these anti-EGFRvIII CAR-engineered T cells produced the effector cytokine, interferon-γ, and lysed antigen-expressing target cells. We concentrated development on a CAR produced from human mAb 139, which specifically recognized GSC lines and glioma cell lines expressing mutant EGFRvIII, but not wild-type EGFR and did not recognize any normal human cell tested. Using the 139-based CAR, T cells from glioblastoma patients could be genetically engineered to recognize EGFRvIII-expressing tumors and could be expanded ex vivo to large numbers, and maintained their antitumor activity. Based on these observations, a γ-retroviral vector expressing this EGFRvIII CAR was produced for clinical application.
Get full access to this article
View all available purchase options and get full access to this article.
References
Bao S.Wu Q.McLendon R.E. et al.2006a. Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature444756-760. Bao, S., Wu, Q., McLendon, R.E., et al. (2006a). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760.
Bao S.Wu Q.Sathornsumetee S. et al.2006b. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factorCancer Res.667843-7848. Bao, S., Wu, Q., Sathornsumetee, S., et al. (2006b). Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843–7848.
Boockvar J.A.Kapitonov D.Kapoor G. et al.2003. Constitutive EGFR signaling confers a motile phenotype to neural stem cellsMol. Cell. Neurosci.241116-1130. Boockvar, J.A., Kapitonov, D., Kapoor, G., et al. (2003). Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol. Cell. Neurosci. 24, 1116–1130.
Bullain S.S.Sahin A.Szentirmai O. et al.2009. Genetically engineered T cells to target EGFRvIII expressing glioblastomaJ. Neurooncol.94373-382. Bullain, S.S., Sahin, A., Szentirmai, O., et al. (2009). Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J. Neurooncol. 94, 373–382.
Chu C.T.Everiss K.D.Wikstrand C.J. et al.1997. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)Biochem. J.324Pt 3855-861. Chu, C.T., Everiss, K.D., Wikstrand, C.J., et al. (1997). Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 324 (Pt 3), 855–861.
Dirks P.B.2006. Cancer: stem cells and brain tumoursNature444687-688. Dirks, P.B. (2006). Cancer: stem cells and brain tumours. Nature 444, 687–688.
Eshhar Z.2010. Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinicCurr. Opin. Mol. Ther.1255-63. Eshhar, Z. (2010). Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr. Opin. Mol. Ther. 12, 55–63.
Hong J.J.Rosenberg S.A.Dudley M.E. et al.2010. Successful treatment of melanoma brain metastases with adoptive cell therapyClin. Cancer Res.164892-4898. Hong, J.J., Rosenberg, S.A., Dudley, M.E., et al. (2010). Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892–4898.
Humphrey P.A.Wong A.J.Vogelstein B. et al.1990. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastomaProc. Natl. Acad. Sci. U.S.A.874207-4211. Humphrey, P.A., Wong, A.J., Vogelstein, B., et al. (1990). Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 87, 4207–4211.
Jemal A.Siegel R.Ward E. et al.2007. Cancer statistics, 2007CA Cancer J. Clin.5743-66. Jemal, A., Siegel, R., Ward, E., et al. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57, 43–66.
Johnson L.A.Sampson J.H.2010. Immunotherapy approaches for malignant glioma from 2007 to 2009Curr. Neurol. Neurosci. Rep.10259-266. Johnson, L.A., and Sampson, J.H. (2010). Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr. Neurol. Neurosci. Rep. 10, 259–266.
Johnson L.A.Morgan R.A.Dudley M.E. et al.2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood114535-546. Johnson, L.A., Morgan, R.A., Dudley, M.E., et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535–546.
Kochenderfer J.N.Yu Z.Frasheri D. et al.2010. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood1163875-3886. Kochenderfer, J.N., Yu, Z., Frasheri, D., et al. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886.
Kochenderfer J.N.Dudley M.E.Feldman S.A. et al.2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsBlood1192709-2720. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720.
Kreisl T.N.Zhang W.Odia Y. et al.2011. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic gliomaNeuro-oncol.131143-1150. Kreisl, T.N., Zhang, W., Odia, Y., et al. (2011). A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncol. 13, 1143–1150.
Lal A.Glazer C.A.Martinson H.M. et al.2002. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasionCancer Res.623335-3339. Lal, A., Glazer, C.A., Martinson, H.M., et al. (2002). Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62, 3335–3339.
Lammering G.Valerie K.Lin P.S. et al.2004. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistanceRadiother. Oncol.72267-273. Lammering, G., Valerie, K., Lin, P.S., et al. (2004). Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. 72, 267–273.
Lee J.Kotliarova S.Kotliarov Y. et al.2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell linesCancer Cell9391-403. Lee, J., Kotliarova, S., Kotliarov, Y., et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391–403.
Liu G.Yuan X.Zeng Z. et al.2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. MolCancer567. Liu, G., Yuan, X., Zeng, Z., et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67.
Lorimer I.A.Keppler-Hafkemeyer A.Beers R.A. et al.1996. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage displayProc. Natl. Acad. Sci. U.S.A.9314815-14820. Lorimer, I.A., Keppler-Hafkemeyer, A., Beers, R.A., et al. (1996). Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. U.S.A. 93, 14815–14820.
Montgomery R.B.Guzman J.O'Rourke D.M.Stahl WL2000. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expressionJ. Biol. Chem.27517358-17363. Montgomery, R.B., Guzman, J., O'Rourke, D.M., and Stahl WL. (2000). Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression. J. Biol. Chem. 275, 17358–17363.
Morgan R.A.2012. Human tumor xenografts: the good, the bad, and the uglyMol. Ther.20882-884. Morgan, R.A. (2012). Human tumor xenografts: the good, the bad, and the ugly. Mol. Ther. 20, 882–884.
Nakayashiki N.Yoshikawa K.Nakamura K. et al.2000. Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptorJpn. J. Cancer Res.911035-1043. Nakayashiki, N., Yoshikawa, K., Nakamura, K. et al. (2000). Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. Jpn. J. Cancer Res. 91, 1035–1043.
Ohno M.Natsume A.Ichiro Iwami K. et al.2010. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigenCancer Sci.1012518-2524. Ohno, M., Natsume, A., Ichiro Iwami, K., et al. (2010). Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 101, 2518–2524.
Park T.S.Rosenberg S.A.Morgan R.A.2011. Treating cancer with genetically engineered T cellsTrends Biotechnol.29550-557. Park, T.S., Rosenberg, S.A., and Morgan, R.A. (2011). Treating cancer with genetically engineered T cells. Trends Biotechnol. 29, 550–557.
Porter D.L.Levine B.L.Kalos M. et al.2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemiaN. Engl. J. Med.365725-733. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733.
Pule M.A.Savoldo B.Myers G.D. et al.2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNat. Med.141264-1270. Pule, M.A., Savoldo, B., Myers, G.D., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270.
Reist C.J.Batra S.K.Pegram C.N. et al.1997. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parentNucl. Med. Biol.24639-647. Reist, C.J., Batra, S.K., Pegram, C.N., et al. (1997). In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl. Med. Biol. 24, 639–647.
Riddell S.R.Greenberg P.D.1990. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cellsJ. Immunol. Methods128189-201. Riddell, S.R., and Greenberg, P.D. (1990). The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128, 189–201.
Rosenberg S.A.Yang J.C.Sherry R.M. et al.2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyClin. Cancer Res.174550-4557. Rosenberg, S.A., Yang, J.C., Sherry, R.M., et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557.
Sampson J.H.Archer G.E.Mitchell D.A. et al.2008. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSemin. Immunol.20267-275. Sampson, J.H., Archer, G.E., Mitchell, D.A., et al. (2008). Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 20, 267–275.
Sampson J.H.Heimberger A.B.Archer G.E. et al.2010. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJ. Clin. Oncol.284722-4729. Sampson, J.H., Heimberger, A.B., Archer, G.E., et al. (2010). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722–4729.
Singh S.K.Hawkins C.Clarke I.D. et al.2004. Identification of human brain tumour initiating cellsNature432396-401. Singh, S.K., Hawkins, C., Clarke, I.D., et al. (2004). Identification of human brain tumour initiating cells. Nature 432, 396–401.
Song D.G.Ye Q.Carpenito C. et al.2011. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Cancer Res.714617-4627. Song, D.G., Ye, Q., Carpenito, C., et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617–4627.
Stupp R.Mason W.P.Van Den Bent M.J. et al.2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN. Engl. J. Med.352987-996. Stupp, R., Mason, W.P., Van Den Bent, M.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996.
Venere M.Fine H.A.Dirks P.B.Rich J.N.2011. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchyGlia591148-1154. Venere, M., Fine, H.A., Dirks, P.B., and Rich, J.N. (2011). Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia 59, 1148–1154.
Weber R.Feng X.Foord O. et al.2005. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofU.S. Patent Office: Pub. No. US 2005/0053608A1March102005US 7628986, issued December 8, 2009. Weber, R., Feng, X., Foord, O., et al. (2005). Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof. U.S. Patent Office: Pub. No. US 2005/0053608A1, March 10, 2005; US 7628986, issued December 8, 2009.
Wikstrand C.J.Hale L.P.Batra S.K. et al.1995. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomasCancer Res.553140-3148. Wikstrand, C.J., Hale, L.P., Batra, S.K., et al. (1995). Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140–3148.
Wong A.J.Ruppert J.M.Bigner S.H. et al.1992. Structural alterations of the epidermal growth factor receptor gene in human gliomasProc. Natl. Acad. Sci. U.S.A.892965-2969. Wong, A.J., Ruppert, J.M., Bigner, S.H., et al. (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 89, 2965–2969.
Zhao Y.Wang Q.J.Yang S. et al.2009. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activityJ. Immunol.1835563-5574. Zhao, Y., Wang, Q.J., Yang, S., et al. (2009). A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574.
Zheng Z.Chinnasamy N.Morgan R.A.2012. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J. TranslMed.1029. Zheng, Z., Chinnasamy, N., and Morgan, R.A. (2012). Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J. Transl. Med. 10, 29.
Zhong X.S.Matsushita M.Plotkin J. et al.2010. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradicationMol. Ther.18413-420. Zhong, X.S., Matsushita, M., Plotkin, J., et al. (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413–420.
Information & Authors
Information
Published In
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published in print: October 2012
Published ahead of print: 24 September 2012
Published online: 10 July 2012
Accepted: 12 June 2012
Received: 19 February 2012
Topics
Authors
Author Disclosure Statement
The authors declare that they have no competing financial interests.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.